Jonathan Young - Jun 13, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jun 13, 2023
Transactions value $
-$29,676
Form type
4
Date filed
6/15/2023, 09:35 PM
Previous filing
Mar 14, 2023
Next filing
Sep 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$29.7K -538 -0.29% $55.16 184K Jun 13, 2023 Direct F1
holding AKRO Common Stock 20K Jun 13, 2023 By EA Irrevocable Trust F2
holding AKRO Common Stock 20K Jun 13, 2023 By CM Irrevocable Trust F2
holding AKRO Common Stock 20K Jun 13, 2023 By JL Irrevocable Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1.
F2 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.